Considerations for the Selection of Written Chinese Variants in the Process of Translating and Linguistically Validating Clinical Outcome Assessments (COAs)

Male hand writing with laptop

Considerations for the Selection of Written Chinese Variants in the Process of Translating and Linguistically Validating Clinical Outcome Assessments (COAs)

As the scale and frequency of clinical trials in the APAC region has increased, pharmaceutical sponsors have encountered challenges in selecting the appropriate written variants of Chinese for translation in a variety of countries.

With this poster, our team has analyzed the written and spoken variants of Chinese and their applicability across countries and regions, providing a detailed discussion of best practices by country.

RWS Life Sciences regularly collaborates with our sponsors on translation, linguistic validation, and eCOA projects supporting clinical trials within APAC and across the globe. Our posters are being presented at the 20th annual European ISPOR conference in Glasgow.